Articles

Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›

Durvalumab in Combination with Chemotherapy as First-Line Treatment for Extensive-Stage SCLC (CASPIAN Data)

2020 Year in Review - Lung Cancer

Platinum Doublet Chemotherapy plus Pembrolizumab for Patients with SCLC: KEYNOTE-604

2020 Year in Review - Lung Cancer

Cediranib Combined with Olaparib in Patients with Platinum-Pretreated SCLC

2020 Year in Review - Lung Cancer

Lurbinectedin for Second-Line Treatment of Patients with Metastatic SCLC

2020 Year in Review - Lung Cancer

Real-World Data for Nivolumab in Patients with Malignant Mesothelioma

2020 Year in Review - Lung Cancer

Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC

2020 Year in Review - Lung Cancer

Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions

2020 Year in Review - Lung Cancer

Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC

2020 Year in Review - Lung Cancer

Combination Ramucirumab and Erlotinib for NSCLC with EGFR Exon 19 or Exon 21 Mutations

2020 Year in Review - Lung Cancer

Page 116 of 376

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.